Inovio Pharmaceuticals
10480 Wateridge Circle
San Diego
California
92121
United States
Tel: 858-597-6006
Website: http://www.inovio.com/
154 articles with Inovio Pharmaceuticals
-
The American Society of Clinical Oncology meeting will be underway next week in Chicago, and companies are preparing to share data from their pipelines. Here's a look.
-
Jacqueline Shea will take over as the new CEO and announced plans to discontinue its Phase III Innovate trial to prioritize its heterologous booster strategy for COVID-19.
-
Inovio shares are down about 2% in premarket trading after cancellation reports of a DNA cancer vaccine collab with AstraZeneca.
-
INOVIO Reports Second Quarter 2021 Financial Results
8/9/2021
INOVIO, a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, reported financial results for the quarter ended June 30, 2021.
-
Clinical Catch-Up: June 7-11
6/14/2021
A busy week for clinical trial news as the ASCO meeting wrapped up and the European Hematology Association 2021 Virtual Congress began. Read on for more. -
2021 COVID-19 News: COVID-19 Possible Spread in Vehicles, US to Share AZ's COVID-19 Vaccine Globa...
4/27/2021
Please check out the biopharma industry's COVID-19 stories that are trending for April 27, 2021. -
With the U.S. Food and Drug Administration’s vaccines advisory committee meeting being held today to discuss the Johnson & Johnson vaccine and blood clotting, there’s even more interest in what’s going on in the pandemic than usual. Here’s a look at some of the top stories.
-
COVID-19 News: Researchers Discover a New Variant, Antiviral Shows Promise in Hamsters and More
4/20/2021
Please check out the biopharma industry's COVID-19 stories that are trending for April 20, 2021. -
Clinical Catch-Up: April 12-16
4/19/2021
It was a particularly busy week for clinical trial news, in part because of several big medical conferences. Here’s a look. -
Shares of Inovio are climbing in early trading this morning after the company announced its DNA vaccine candidate for COVID-19 induced a robust T-cell response against multiple variants of the SARS-CoV-2 virus.
-
QIAGEN and INOVIO Expand Collaboration to Develop Next Generation Sequencing (NGS) Companion Diagnostic for INOVIO’s VGX-3100 for Advanced Cervical Dysplasia
2/24/2021
Liquid biopsy-based precision test guides patient selection and offers potential for cost-effective, non-invasive alternative to surgical removal of cervical lesions
-
INOVIO and QIAGEN expand collaboration to develop next generation sequencing (NGS) companion diagnostic for INOVIO's VGX-3100 for advanced cervical dysplasia
2/24/2021
Liquid biopsy-based precision test guides patient selection and offers potential for cost-effective, non-invasive alternative to surgical removal of cervical lesions
-
INOVIO Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
1/25/2021
INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, including COVID-19, cancer and HPV-associated diseases, today announced the closing of its previously announced underwritten public offering of 20,355,000 shares of its common stock
-
INOVIO Announces Pricing of Public Offering of Common Stock - Jan 21, 2021
1/21/2021
INOVIO Pharmaceuticals, Inc., a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, including COVID-19, cancer and HPV-associated diseases, announced the pricing of an underwritten public offering of 17,700,000 shares of its common stock at a public offering price of $8.50 per share.
-
INOVIO Announces Proposed Public Offering of Common Stock
1/20/2021
INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, including COVID-19, cancer and HPV-associated diseases, today announced that it has commenced an underwritten public offering of $150 million of shares of its common stock.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 17, 2020.
-
Biopharma companies wrapped up September and headed into October with plenty of clinical trial news. Here’s a look.
-
Pennsylvania-based Inovio said the regulatory agency has additional questions about the Phase II/III trial regarding the vaccine candidate itself, known as INO-4800, as well as the company’s Cellectra 2000 delivery device.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 9, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 1, 2020.